Skip to search formSkip to main contentSkip to account menu

SU 14813

Known as: SU-14813, SU14813 
National Institutes of Health

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2011
2011
The Discovery and Development of SU14813, a Next-Generation Multitargeted Tyrosine Kinase Inhibitor for the Treatment of Human Malignancies
Commentary on: [Shem Patyna, A. Douglas Laird, Dirk B. Mendel, Anne-Marie O'Farrell, Chris Liang, Huiping Guan, Tomas Vojkovsky… 
2010
2010
Evaluation of CXCR4 inhibition in the prevention and intervention model of laser-induced choroidal neovascularization.
PURPOSE. Endothelial precursor cells (EPCs) derived from hematopoietic stem cells (HSCs) have been shown to contribute to… 
2008
2008
Gateways to clinical trials.
Gateways to Clinical Trials are a guide to the most recent clinical trials in current literature and congresses. The data in the… 
2006
2006
SU 14813 : a novel multiple receptor tyrosine kinase inhibitor with potent antiangiogenic and antitumor activity
Receptor tyrosine kinases (RTK), such as vascular endothelial growth factor receptor (VEGFR), platelet-derived growth factor… 
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)